Skip to content
Try Mental Wellness – Lifestyle
Author:
BioNTech SE
BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026
April 21, 2026
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
April 11, 2026
BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer
March 24, 2026
←
Previous Page
1
2